APPENDIX 16: INTERVENTIONS FOR ACUTE DEPRESSION – STUDY CHARACTERISTICS

Pharmacological interventions

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
Aripiprazole compared with placebo											
BRISTOLMYERSSQUIB2006	USA	39	63%	100%	None	186	162	Aripiprazole	10mg	14	8
						188	177	Placebo	N/A	14	8
BRISTOLMYERSSQUIB2007	USA	40	60%	100%	None	187	175	Aripiprazole	10mg	14	8
						188	176	Placebo	N/A	14	8
QUANTE2010	DE	51	48%	74%	Citalopram with lithium or valproate	12	8	Aripiprazole	15mg	7	6
						11	10	Placebo	N/A	7	6
Bupropion, sertraline and venlafaxine											
POST2006	USA, NLD, DEU	42	50%	73%	Mood stabilizer and/or an antipsychotic	51	51	Bupropion	280mg	7	10
						58	58	Setraline	190mg	7	10
						65	65	Venlafaxine	195mg	7	10
Imipramine compared with moclobemide											
SILVERSTONE2001	USA	37	100%	0%	Mood stabilizers, single benzodiazepine hypnotic	75	75	Imipramine	150mg	7	8
						81	81	Moclobemide	600mg	7	8
Lamotrigine compared with placebo											
CALABRESE1999	USA, UK, FRA, AUS	41	60%	100%	None	66	64	Lamotrigine	50mg	14	7
						63	63	Lamotrigine	200mg	14	7
						66	65	Placebo	Placebo	14	7
CALABRESE2005	USA, UK, FRA,	41	60%	100%	Benzodiazepines (limited use)	181	NR	Quetiapine	300mg	7	8
						180	NR	Quetiapine	600mg	7	8

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
	AUS					181	NR	Placebo	N/A	7	8
CALABRESE2008a	USA	41	62%	NR	NR	103	102	Lamotrigine	200mg	7	10
						103	100	Placebo	N/A	7	10
CALABRESE2008b	USA	37	55%	100%	NR	133	126	Lamotrigine	200mg	7	8
						124	117	Placebo	N/A	7	8
CALABRESE2008c	USA	37	64%	0%	NR	111	109	Lamotrigine	200mg	7	8
						110	105	Placebo	N/A	7	8
CALABRESE2008d	USA	38	54%	100%	NR	131	123	Lamotrigine	200mg	7	8
						128	120	Placebo	N/A	7	8
VANDERLOOS2009	NLD, ESP	46	54%	68%	Lithium	64	64	Lamotrigine	200mg	7	8
						60	60	Placebo	N/A	7	8
Lamotrigine, gabapentin and placebo											
FRYE2000	USA	NR	58%	35%	Levothyroxine, triiodothyronine and clonazepam allowed in phase I	NR	NR	Lamotrigine	300mg	7	6
						NR	NR	Gabapentin	3980mg	7	6
						NR	NR	Placebo	N/A	7	6
Lurasidone compared with placebo											
SUNOVION2012a	DEU, IND, POL, ROU, RUS, ZAF, UKR, USA	42	48%	100%	Lithium or valproate allowed	183	179	Lurasidone	65mg	7	6
						165	161	Placebo	N/A	7	6

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
SUNOVION2012b	USA, UK, FRA, AUS	41	60%	100%	Lithium or valproate allowed	166	161	Lurasidone	32mg	7	6
						169	162	Lurasidone	80mg	7	6
						170	162	Placebo	N/A	7	6
Olanzapine compared with placebo											
TOHEN2012	JPN, CHN, TWN, KOR, USA	36	58%	100%	NR	343	343	Olanzapine	10mg	7	6
						171	171	Placebo	N/A	7	6
Olanzapine and fluoxetine combination compared with lamotrigine											
BROWN2006	USA	37	60%	100%	Anticholinergics, benzodiazepines or other hypnotics allowed	205	202	Olanzapine & fluoxetine	10.7mg/40.8mg	7	7
						205	191	Lamotrigine	106.4mg	7	7
Olanzapine and fluoxetine combination, olanzapine and placebo											
TOHEN2003	USA	37	57%	67%	Lorazepam and anticholinergic therapy	86	82	Olanzapine & fluoxetine	7.4mg/39.3mg	7	8
						370	351	Olanzapine	9.7mg	7	8
						377	355	Placebo	N/A	7	8
Paroxetine, imipramine and placebo											
NEMEROFF2001	USA	36	NR	70%	Lithium, valproate and/or carbamazepine	35	33	Paroxetine	32.6mg	7	10
						39	36	Imipramine	166.7mg	7	10
						43	43	Placebo	N/A	7	10
Quetiapine compared with placebo											

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
SUPPES2010	USA	39	65%	80%	Lorazepam, zolpidem tartrate, zaleplon, zopiclone, chloral hydrate and anticholinergics allowed	140	133	Quetiapine XR	300mg	7	8
						130	137	Placebo	N/A	7	8
THASE2006	USA	37	57%	67%	Lorazepam and zolpidem tartrate allowed	172	155	Quetiapine	300mg	7	8
						169	151	Quetiapine	600mg	7	8
						168	161	Placebo	N/A	7	8
Quetiapine compared with paroxetine											
MCELROY2010	Multiple (not specified)	42	59%	62%	Lorazepam, zolpidem tartrate and chloral hydrate allowed	245	229	Quetiapine	300mg	7	8
						247	232	Quetiapine	600mg	7	8
						122	118	Paroxetine	20mg	7	8
						126	121	Placebo	N/A	7	8
Quetiapine, lithium and placebo											
YOUNG2010	Multiple (not specified)	42	59%	62%	Lorazepam, zolpiclone tartrate, zaleplon, zopliclone and chloral hydrate allowed	265	255	Quetiapine	300mg	7	8
						268	263	Quetiapine	600mg	7	8
						136	136	Lithium	490.5mg	7	8
						133	129	Placebo	N/A	7	8
Valproate compared with placebo											

Study	Country	Age	% Female	% BPI	Concomitant medication	N Rand	N Post	Group	Dose	Freq	Dur
DAVIS2005	USA	41	11%	100%	Bedtime sedatives allowed	13	13	Valproate	1250mg	7	8
						12	12	Placebo	N/A	7	8
GHAEMI2007	USA	37	50%	50%	None	10	9	Valproate	1028.8mg	7	6
						8	9	Placebo	N/A	7	6
MUZINA2011	USA	39	57%	37%	Lorazepam and zolpidem allowed	26	26	Valproate	1606mg	7	6
						28	28	Placebo	N/A	7	6
Ziprasidone compared with placebo											
PAKAR2012	USA	39	53%	40%	Treatment as usual	NR	NR	Ziprasidone	80–160 mg	7	6
						NR	NR	Placebo	N/A	7	6
PFIZER2009a	USA	20	57%	100%	None	185	NR	Ziprasidone	40mg	14	6
						196	NR	Placebo	N/A	14	6
PFIZER2009b	USA, UK, FRA, AUS	41	60%	100%	None	171	NR	Ziprasidone	20mg	14	6
						165	NR	Ziprasidone	40mg	14	6
						168	NR	Placebo	N/A	14	6
SACHS2011	AUS, IND, USA	40	61%	100%	Lamotrigine, lithium or valproate; lorazepam allowed	148	147	Ziprasidone	40mg	14	6
						150	147	Placebo	N/A	14	6

Nutritional interventions

Nutritional interventions											
Omega-3 fatty acids compared with placebo											
KECK2006B	NR	45	48%	74%	Mood stabilizers	59	NR	Eicosapentaenoic acid	6000mg	7	17
						57	NR	Placebo	N/A	7	17

Physical interventions

Physical interventions											
Acupuncture compared with sham acupuncture											
DENNEHY2009B	USA	41	69%	38%	Medication as usual	13	NR	Acupuncture	N/A	1.5	8
						13	NR	Sham	N/A	1.5	8
Bright light therapy compared with low-density and high density air ionization											
DAUPHINAIS2012	USA	43	74%	NR	Medication as usual	18	10	Bright light therapy	N/A	7	8
						20	11	Low-density negative air ionization	N/A	7	8
						6	2	High-density negative air ionization	N/A	7	8
Chronotherapeutic augmentation treatment (CAT) compared with treatment as usual (TAU)											
WU2009	USA	39	41%	NR	Lithium and antidepressants	32	32	Sleep deprivation, bright light therapy and sleep phase advance	N/A	1	7
						17	17	TAU	N/A	1	7
Transcranial magnetic stimulation (TMS) compared with sham TMS											
NAHAS2003	USA	43	61%	61%	Carbamazepine, valproate or combination	11	11	TMS	20 mins	7	2
						12	12	Sham TMS	20mins	7	2